Table 1.
Baseline demographics of the study group
| Skin AF ≤2.2 (n = 71) | Skin AF >2.2 (n = 68) | P value | |
|---|---|---|---|
| Age (years) | 61.34 ± 11.34 | 66.57 ± 8.38 | 0.01 |
| Gender (M/F) | 41/30 | 43/25 | 0.51 |
| Skin AF (A.U.) | 1.90 ± 0.27 | 2.71 ± 0.31 | 0.01 |
| BMI (kg/m2) | 26.50 ± 3.86 | 26.05 ± 3.25 | 0.74 |
| SBP (mmHg) | 142.36 ± 14.83 | 139.06 ± 16.81 | 0.22 |
| DBP (mmHg) | 80.80 ± 13.57 | 75.41 ± 9.46 | 0.01 |
| PP (mmHg) | 61.92 ± 12.70 | 63.94 ± 14.64 | 0.39 |
| Hypertension, n (%) | 59 (83.10) | 57 (83.82) | 0.91 |
| DM, n (%) | 0.06 | ||
| None, n (%) | 50 (70.42) | 40 (58.82) | |
| OHA, n (%) | 20 (28.17) | 21 (30.88) | |
| RI, n (%) | 1 (1.41) | 7 (10.29) | |
| Hyperlipidemia, n (%) | 57 (80.28) | 52 (76.47) | 0.59 |
| Stroke, n (%) | 3 (4.23) | 7 (10.29) | 0.17 |
| IHD, n (%) | 9 (12.68) | 21 (30.88) | 0.01 |
| PAOD, n (%) | 1 (1.41) | 1 (1.47) | 0.98 |
| eGFR (mL/min/1.73 m2) | 66.64 ± 17.77 | 62.06 ± 22.73 | 0.19 |
| Antiplatelets, n (%) | 48 (67.61) | 43 (63.24) | 0.59 |
| β-Blockers, n (%) | 25 (35.21) | 34 (50.00) | 0.08 |
| CCBs, n (%) | 29 (40.85) | 33 (48.53) | 0.36 |
| ACEIs/ARBs, n (%) | 49 (69.01) | 43 (63.24) | 0.47 |
| Statins, n (%) | 40 (56.34) | 41 (60.29) | 0.64 |
| Smoking | 0.06 | ||
| Never, n (%) | 55 (77.46) | 40 (58.82) | |
| Ever, n (%) | 10 (14.08) | 19 (27.94) | |
| Active, n (%) | 6 (8.45) | 9 (13.24) |
Skin AF skin autofluorescence, AU arbitrary unit, BMI body mass index, SBP systolic blood pressure, DBP, diastolic blood pressure, PP pulse pressure, DM diabetes mellitus, OHA oral hypoglycemic agent, RI regular insulin, IHD ischemic heart disease, GFR glomerular filtration rate, CCBs calcium channel blockers, ACEIs angiotensinogen converting enzyme inhbitors, ARBs angiotensin II type I receptor blockers